Latigo BiotherapeuticsLTGO
Recorded

Latigo Biotherapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration24 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

And our third annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the senior biotech analysts here at the firm. It is my pleasure to welcome our next presenting company, Latigo Biotherapeutics. From the company, we have the chief, or newly minted Chief Executive Officer, Todd Smith. Todd, I've prepared a Q&A for you, but why don't you make some opening comments? You just joined the company, I would say last week, or just a few days ago. How was the transition? Why you joined at this juncture? And just maybe introduce the Latigo story to our audience.

Todd SmithCEO

Yeah. Well, first of all, thank you, and good morning, everybody. As Yatin mentioned, I'm brand new. This is my day four as the CEO of Latigo. Excited to join it, right? I think one of the things Latigo's trying to do, we're trying to build ourselves into the innovative pain company. And I'd been on the board since early summer and got to see the pretty amazing team. I got to see the progression of the clinical data, both for LTG-321 and for onzotrigine. And so, for me, very excited to join the team and continue to help them build out what they've started. They had a very successful IPO. And so, my background, which might help understand why I'm stepping in at this time, is really centered around commercial, building out companies, launching products, and commercializing in this space.

Todd SmithCEO

I have over 15 products that I've been able to launch or manage in the pain space. Recently, I just sold a company called Corium to Collegium. Wrapped that up at the end of summer. It was a company that was underperforming commercially and operationally. We were able to turn it around in about 20 months, and then had an exit for the investors that returned fully back to the investors at that time. So, that made me available at the end of summer, and as we worked with the board, determined that as the next phase for Latigo is in this commercial build-out, commercial preparation for onzotrigine launch, seemed like the right time to make that change. I had some other opportunities. I made the decision to step in.

Todd SmithCEO

I think with that, my background then further goes into, which I think is important for everybody to understand, was at Horizon Pharma as the first Chief Commercial Officer. Got the first product approved. We IPO'd, and then we launched, and launched subsequently about five pain and NRA products at that time, and obviously had success there. So, I'm excited to be joining at this time. I think we have a lot of excitement as we look at next year. Second half of next year, we should have two readouts for both the OA trial for LTG-321, and we should have it for the bunionectomy trial for onzotrigine. We are also excited about the deeper pipeline as we look at LTG-418, which is a novel product unto itself with potentially more potency and the ability to continue to be once a day as well.

Todd SmithCEO

And then we have further work being done to look at other assets and targets as we continue to build out Latigo.

Operator

Got it. Very good. Todd Smith, thank you for that intro. Maybe just stepping back at a high level, pain has always been a very difficult area, right? I think it was only until after Vertex came up with their molecule we started seeing more development happening. If you look at the space, what do you think why we are seeing sort of this development or interest in the pain space?

Todd SmithCEO

Yeah. No, it's a great question because one of the things, as someone who's been in pain for, gosh, over 30 years, launched one of the first really novel pain drugs after the opioids, launching ketorolac back in the early 1990s, realizing how innovative that was, and then seeing some of the innovation in pain drugs through the late 1990s, early 2000s. Then there was really nothing at that point, right? What was kind of characteristic was this focus on the opioid crisis. I think there wasn't a whole lot of new things coming out, so I think on top of that, I think people just kind of settled in. We had NSAIDs, we had opioids. You have kind of two sides of this picture.

Todd SmithCEO

Opioids obviously have the societal risk and the human risk of overdose, but they also have clinically suboptimal when you think about great pain management, but clinical experience is very difficult, right? You have dizziness, you have OIC, you have inability to kind of release patients because of all these issues, and it's difficult. On the other side, you have the NSAIDs, which again have their own success and properties, whether it's anti-inflammatory and anti-pain, but they have significant side effects as well. At some point, pain's such a critical part. We have over 80 million people in the U.S. that have pain related around OA or acute pain. So there is a need for something new when you have that big of a need. I think people have always said pain's the largest unmet need market out there, right?

Todd SmithCEO

Then you start to see the validation of the NaV targets, the 1.8 particularly as lead. I think Vertex obviously launched about two years ago now, the NaV1.8, and they validated the asset, the class. I think we see it, right? They have over 2 million scripts on a run rate basis and growing. They grew 50% quarter-over-quarter in script volume. Yet, as novel and as important as suzetrigine is from Vertex, we know that it doesn't have quite the efficacy that I think most pain doctors would say, "Hey, that's a game changer for them." We saw that they also have drug-drug interactions. Again, a good product validating the class, but then we see obviously a lot of other groups, ourselves included, leading with NaV1.8. We see obviously other companies starting to build it out.

Todd SmithCEO

There is definitely a need, and I think we're also looking at multimodal with 1.7s, 1.9s, the Kvs. So there's a great resurgence now in innovation, development, and then ultimately what comes with that is you'll see then further work being done around investigator-initiated studies. You'll see work being done on testing other. That's great for the space because there's clearly a need for better treatments. There's clearly a need economically for better outcomes, and ultimately physicians are always seeking the best way to treat patients, and when that doesn't exist, we'll see them move towards that. Now what we need to do is continue to work on the market around either policy and then ultimately payers.

Operator

Got it. Very good. Thank you for that. Let's just focus on the molecules that you have. So onzotrigine, could you talk about how that product is designed to differentiate from JOURNAVX, and maybe touch a little bit on the data that you have already generated in abdominoplasty?

Todd SmithCEO

Yeah. This is one of the reasons I got very excited is I think when, as people know, onzotrigine data, initial abdominoplasty data got published in The New England Journal of Medicine in the summer. When you see that data, you get very excited, right? I think the SPID48 scores of 62, they showed about a 50% better response than Vicodin and about a 30% better response than suzetrigine when you look at cross-trial comparison. I think the other thing, and most importantly for me, which I thought was exciting just as someone who has commercialized eventually in the market, was the 53-minute onset. When you look at that compared to suzetrigine of 119 minutes, you saw a two and a half faster onset of pain relief.

Todd SmithCEO

And then I think finally, as we think about what we talked about before with opioids and NSAIDs on both sides, good products for pain relief, but has a little bit of a messy profile when it comes to it. What we really have an opportunity to do with the NaV1.8 class is really come out with something that manages pain as effectively as these classes, but is very clean. And one of the other differences we saw is that we do not have drug-drug interactions with the initial data we are seeing, whereas I think we look at suzetrigine and the one thing they do have is some of the drug-drug interactions around the CYP3A.

Todd SmithCEO

For me, I got pretty excited when I think, number one, in the marketplace, I think every doctor will tell you, every patient will tell you, at the end of the day, how they determine the efficacy or whether a drug is working is really just onset.

Todd SmithCEO

Yeah. The fact that we had that 53 minutes versus 119, two and a half times faster, is a differentiator that is significant.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day